RecruitingRecruiting
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly Diagnosed Active Crohn Disease
NCT06890650 · All India Institute of Medical Sciences
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Efficacy of Microbiome Manipulation Strategies (fecAL Microbial Transplantation OR CDED OR Both) in Combination Standard Medical Therapy for Induction and Maintenance of Remission in Mild to Moderate tReatment naÃive Active Crohns Disease (ALTER-CD): a Multicentre Double-blind Factorial Randomized Controlled Trial
About this study
This study is a multi-center, double-blind, factorial randomized controlled trial designed to evaluate the efficacy of microbiome manipulation strategies using fecal microbiota transplantation (FMT), Crohn's Disease Exclusion Diet (CDED), or their combination in treatment-naïve patients with mild to moderate active Crohn's Disease (CD).
Study Setting
The trial is conducted at six FMT centers across India, with one additional center dedicated to microbiome analysis:
AIIMS, New Delhi, India Dayanand Medical College, Ludhiana, India PGIMER, Chandigarh, India Lisie Hospital, Kochi, India IMS, BHU, Varanasi, India Sion Hospital, Mumbai, India IIIT-Delhi, India(for microbiome analysis)
Intervention Details:
Fecal Microbiota Transplantation (FMT)- Patients receive a 3-day course of oral vancomycin (500 mg BD) before the first FMT.
Freshly prepared 50 g stool is used for each FMT, and the transplant is administered within 4 hours of preparation.
FMT is delivered via colonoscopy at weeks 0, 2, and 6, followed by 8-weekly maintenance sessions for responders at weeks 10, 18, 26, 34, 42.
Multiple donors (n≥2) are used to ensure microbiome diversity. The first FMT session is instilled in the right colon/terminal ileum post bowel preparation, whereas maintenance sessions involve left-colon infusion without bowel preparation.
Crohn's Disease Exclusion Diet (CDED)- Patients assigned to CDED follow a phased dietary protocol designed to limit exposure to pro-inflammatory dietary components and enhance gut microbiome stability.
CDED consists of an induction and maintenance phase, with structured dietary charts and counseling provided by a dietitian.
Compliance is monitored via telephonic interviews and a dedicated diet tracking app (IBD NutriCare).
Sham Interventions- Sham FMT: Patients receive sterile water or saline infusions via colonoscopy at the same time points as FMT.
Sham Diet: Patients receive general dietary advice but do not follow the CDED protocol.
Randomization and Blinding- Central randomization is conducted using a secure web-based system (REDCap), utilizing stratified randomization based on disease extent.
The study follows a double-blind approach:
Blinded: Patients, clinical assessors, and endoscopic scorers. Unblinded: Endoscopists administering FMT/sham FMT and dietitians providing dietary counseling.
Oral vancomycin and placebo capsules are identically packed to maintain blinding.
Data Collection and Assessments- Baseline Assessments (Week 0) Clinical Assessment: Crohn's Disease Activity Index (CDAI), symptom scoring, and dietary adherence evaluation.
Laboratory Tests: Hemogram, renal/liver function, CRP, ESR, fecal calprotectin, and microbiome profiling.
Endoscopy: SES-CD scoring with high-definition endoscopic video recording. Histology: Biopsy samples are analyzed using Distribution Chronicity and Activity (DCA) scoring.
Follow-up Assessments- Clinical assessments at weeks 0, 2, 4, 6, 10, and every 8 weeks thereafter. Endoscopic assessments at baseline, week 10, and week 48, with central reading of all videos.
Fecal microbiome analysis at baseline, week 10, and week 48. Safety and Monitoring- Adverse Events (AEs) graded per CTCAE criteria (Grades 1-5). Serious Adverse Events (SAEs) include hospitalization, life-threatening conditions, or death.
DSMB reviews interim safety data at week 10 and 24. Emergency unblinding is permitted for critical medical decisions. Data Management- Data is collected using REDCap, with role-based access controls. Endoscopic images and videos are securely stored for centralized analysis. Microbiome sequencing data is processed at IIIT-Delhi. Statistical Considerations- Sample size calculation: 168 patients (42 per arm, 90% power).
Analysis Plan:
Intention-to-treat (ITT) and per-protocol (PP) analyses. Longitudinal mixed-effects modeling for microbiome shift
Eligibility criteria
Inclusion Criteria:
1. Patients with treatment-naive Crohns disease accessible with ileocolonoscopy
2. Symptom onset of less than 12 months
3. Mild to moderate disease activity with endoscopically active disease
1. CDAI of greater than 150 and less than 450
2. SES-CD of or equal to or greater than 6 (or equal to or greater than 4 if isolated ileal disease)
4. Aged between 18-75 years
Exclusion Criteria:
1. Patients with severe disease (CDAI greater than 450, SES-CD greater than 16) or requiring hospitalization
2. Patients who have been received on corticosteroids, immunosuppressants (azathioprine/ 6- mercaptoprine/methotrexate) for greater than 2 weeks
3. Biologicals or small molecule exposure
4. Stricturing (non-passable stricture), fistulising phenotype or perianal fistula/abscess
5. L4 disease
6. Pregnant or lactating women
7. Previous surgery for CD
8. Declining consent
9. Not willing for FMT/Dietary advise
10. Patients with current or recent history of clinically severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological disease.
11. Positive assay or stool culture for pathogens (ova and parasite examination, bacteria) or positive test for Clostridioides difficile toxin at screening#
12. Patients infected with human immunodeficiency virus (HIV) # The patients with positive assay will be treated appropriately and tests will be repeated. Those with negative assay and persistent activity will be included in the study.
Study design
Enrollment target: 168 participants
Allocation: randomized
Masking: double
Age groups: adult, older_adult
Timeline
Starts: 2025-03-15
Estimated completion: 2028-03-15
Last updated: 2025-04-04
Interventions
Other: Fecal Microbial TransplantationOther: Sham transplantationOther: Crohns disease exclusion dietOther: Sham diet
Primary outcomes
- • Proportion of patients with clinical remission and endoscopic response at week 10 (10 weeks)
- • Proportion of patients with clinical remission and endoscopic remission at week 48 (48 weeks)
Sponsor
All India Institute of Medical Sciences · other
With: Post Graduate Institute of Medical Education and Research, Chandigarh, Dayanand Medical College and Hospital, Institute of Medical Sciences of the Banaras Hindu University, India, Lokmanya Tilak Municipal Medical College and Hospital, Lisie Hospital, Indraprastha Institute of Information Technology Delhi, Indian Council of Medical Research
Contacts & investigators
ContactProf Vineet Ahuja, DM Gastroenterology · contact · vineet.aiims@gmail.com · +91-9810707170
ContactDr Himanshu Narang, DM Gasteroentrology · contact · h92narang@gmail.com · +91-8800316504
InvestigatorProf Vineet Ahuja, DM Gastroenterology · principal_investigator, Department of Gastroenterology, AIIMS, New Delhi
All locations (6)
Department of Gastroenterology, Lisie HospitalNot Yet Recruiting
Kochi, Kerala, India
Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, SionNot Yet Recruiting
Mumbai, Maharashtra, India
Department of Gastroenterology and Human Nutrition, All India Institute of Medical SciencesRecruiting
New Delhi, National Capital Territory of Delhi, India
Department of Gastroenterology, Dayanand Medical CollegeNot Yet Recruiting
Ludhiana, Punjab, India
Department of Gastroentrology, Postgraduate Institute of Medical Education and ResearchNot Yet Recruiting
Chandigarh, Punjab/Haryana, India
Department of Gastroenterology, Institute of Medical Sciences, Banaras Hindu UniversityNot Yet Recruiting
Varanasi, Uttar Pradesh, India